-
公开(公告)号：EP3551225A1
公开(公告)日：2019-10-16
申请号：EP17818020.4
申请日：2017-12-07
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
发明人： VAN DIJK, Marc , MUNDT, Cornelia Anne , RITTER, Gerd , SCHAER, David , WOLCHOK, Jedd David , MERGHOUB, Taha , WILSON, Nicholas Stuart , SAVITSKY, David Adam , FINDEIS, Mark Arthur , ZAPPASODI, Roberta , HOLMGAARD, Rikke Bæk , CUILLEROT, Jean-Marie , PROSCURSHIM, Igor , SHEBANOVA, Olga
IPC分类号： A61K39/395 , C07K16/28
-
公开(公告)号：EP3383431A1
公开(公告)日：2018-10-10
申请号：EP16871589.4
申请日：2016-12-02
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd
发明人： WILSON, Nicholas S. , WAIGHT, Jeremy D. , RITTER, Gerd , TSUJI, Takemasa , LEGER, Olivier , SEIBERT, Volker , SCHAER, David , MERGHOUB, Taha , UNDERWOOD, Dennis J. , GONZALEZ, Ana M. , VAN DIJK, Marc
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2878 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/76
摘要： The present disclosure provides antibodies that specifically bind to human GITR, as well as compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and deactivate, reduce, or inhibit GITR activity. The present disclosure also provides methods for treating autoimmune or inflammatory diseases disorders, by administering an antibody that specifically binds to human GITR and deactivates, reduces, or inhibits GITR activity.
-
公开(公告)号：EP3383430A1
公开(公告)日：2018-10-10
申请号：EP16871583.7
申请日：2016-12-02
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd
发明人： WILSON, Nicholas S. , WAIGHT, Jeremy D. , RITTER, Gerd , SCHAER, David , HIRSCHHORN-CYMERMAN, Daniel , MERGHOUB, Taha , BREOUS-NYSTROM, Ekaterina V. , SEIBERT, Volker , TSUJI, Takemasa , LEGER, Olivier , UNDERWOOD, Dennis J. , VAN DIJK, Marc
IPC分类号： A61K39/395 , A61K47/68 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2827 , C07K16/30 , C07K2317/30 , C07K2317/31 , C07K2317/732 , C07K2317/75 , C07K2317/76
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：EP3292152A1
公开(公告)日：2018-03-14
申请号：EP16723616.5
申请日：2016-05-06
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
发明人： VAN DIJK, Marc , BREOUS-NYSTROM, Ekaterina , SEIBERT, Volker , RITTER, Gerd , SCHAER, David , HIRSCHHORN-CYMERMAN, Daniel , MERGHOUB, Taha , TANG, Hao , SAVITSKY, David A. , WAIGHT, Jeremy , WILSON, Nicholas S.
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2875 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/524 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/71 , C07K2317/74 , C07K2317/75 , C07K2317/92 , G01N33/6863 , G01N2333/70578
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：EP3498295A1
公开(公告)日：2019-06-19
申请号：EP18204948.6
申请日：2015-05-28
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd
发明人： UNDERWOOD, Dennis J. , LÉGER, Olivier , SEIBERT, Volker , VAN DIJK, Marc , SCHAER, David , TSUJI, Takemasa , RITTER, Gerd , GONZALEZ, Ana M. , WILSON, Nicholas S. , ZAPPASODI, Roberta , MEGHOUB, Taha , WOLCHOK, Jedd David
IPC分类号： A61K39/395 , C07K16/28
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e . g ., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e . g ., enhances, activates or induces GITR activity.
-
公开(公告)号：EP3344656A1
公开(公告)日：2018-07-11
申请号：EP16763697.6
申请日：2016-09-01
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
发明人： VAN DIJK, Marc , MUNDT, Cornelia, Anne , RITTER, Gert , WOLCHOK, Jedd, David , MERGHOUB, Taha , ZAPPASODI, Roberta , HOLMGAARD, Rikke, Bæk , SCHAER, David , SAVITSKY, David, Adam , WILSON, Nicholas, Stuart
CPC分类号： C07K16/2818 , A61K2039/507 , C07K16/2803 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/92
摘要： The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
-
公开(公告)号：EP3148579A1
公开(公告)日：2017-04-05
申请号：EP15729987.6
申请日：2015-05-28
申请人： Agenus Inc. , Memorial Sloan Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd
发明人： UNDERWOOD, Dennis J. , LEGER, Olivier , SIEBERT, Volker , VAN DIJK, Marc , SCHAER, David , TSUJI, Takemasa , RITTER, Gerd , GONZALEZ, Ana M. , WILSON, Nicolas S. , ZAPPASODI, Roberta , MERGHOUB, Taha , WOLCHOK, Jedd David
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2878 , A61K35/17 , A61K2039/507 , C07K16/2809 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/502 , G01N2333/70578
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
摘要翻译： 本公开提供了特异性结合人类糖皮质激素诱导的TNFR家族相关受体（GITR）的抗体和包含此类抗体的组合物。 在具体方面，所述抗体与所述抗体特异性结合人GITR并调节GITR活性，例如增强，激活或诱导GITR活性。 本公开还提供了通过施用特异性结合人GITR并调节GITR活性的抗体（例如增强，激活或诱导GITR活性）来治疗疾病如癌症和感染性疾病的方法。
-
公开(公告)号：EP4289484A3
公开(公告)日：2024-03-06
申请号：EP23190631.4
申请日：2017-12-07
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd. , Memorial Sloan-Kettering Cancer Center
发明人： VAN DIJK, Marc , MUNDT, Cornelia Anne , RITTER, Gerd , SCHAER, David , WOLCHOK, Jedd David , MERGHOUB, Taha , WILSON, Nicholas Stuart , SAVITSKY, David Adam , FINDEIS, Mark Arthur , UNDERWOOD, Dennis John , CUILLEROT, Jean-Marie , PROSCURSHIM, Igor , SHEBANOVA, Olga
摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
-
公开(公告)号：EP4289484A2
公开(公告)日：2023-12-13
申请号：EP23190631.4
申请日：2017-12-07
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd. , Memorial Sloan-Kettering Cancer Center
发明人： VAN DIJK, Marc , MUNDT, Cornelia Anne , RITTER, Gerd , SCHAER, David , WOLCHOK, Jedd David , MERGHOUB, Taha , WILSON, Nicholas Stuart , SAVITSKY, David Adam , FINDEIS, Mark Arthur , UNDERWOOD, Dennis John , CUILLEROT, Jean-Marie , PROSCURSHIM, Igor , SHEBANOVA, Olga
IPC分类号： A61P35/04
摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
-
公开(公告)号：EP3551660A1
公开(公告)日：2019-10-16
申请号：EP17818406.5
申请日：2017-12-07
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.048 秒)
